New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute ...
Randomised controlled trial with over 25,000 participants suggests that using the antiviral, molnupiranir, does not decrease deaths or hospital admissions among patients with COVID-19 infection who ...
In a recent study published in BMJ, researchers examine whether molnupiravir administration during the initial five days of acute coronavirus disease 2019 (COVID-19) could lower post-acute sequelae of ...
In a recent study posted to the medRxiv* server, researchers evaluated the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, nirmatrelvir-ritonavir, and ...
A drug widely used to treat COVID-19 might be spurring the evolution of new SARS-CoV-2 variants. The drug, molnupiravir, works by introducing a flurry of mutations to the viral genome; this helps to ...
There are currently two approved COVID-19 treatments that can be taken orally: nirmatrelvir-ritonavir (known as Paxlovid and developed by Pfizer) and Merck’s molnupiravir. They have both been shown to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...
SWEDESBORO, N.J.--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has ...
A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback